Login to Your Account

FDA Wants More Data

MannKind Slides on Second Afrezza Complete Response

By Jennifer Boggs

Thursday, January 20, 2011
It was just as MannKind Corp.'s bearish investors predicted when the FDA said it was extending the PDUFA date for inhaled insulin candidate Afrezza: The agency issued a complete response letter – the second – for use of the product in Type I and Type II diabetes.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription